SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rh…
Author: Eyewire Today
ICAD: Eyes Spot Early Alzheimer’s
The eyes are a window into the brain for many disorders, and Alzheimer’s disease may be no exception, a researcher said here. In a pilot study, retinal scans to measure blood vessel thickness at the back of the eye showed strong correlations with the l…
PowerVision Adds Medtronic as a Strategic Investor
PowerVision, Inc., a private company developing an accommodating intraocular lens, announced that it had added Medtronic to its list of investors in a recent closing of its Series C financing. Stephen Oesterle, MD, Senior Vice President, Medicine and T…
Novartis Fails to Win UK Backing for Lucentis in Diabetic Eye Condition
Novartis AG, Europes second-largest drugmaker, failed to win approval from the U.K.s health-cost agency for its drug Lucentis in diabetics who suffer an eye condition. Lucentis wasnt cost effective in patients with macular edema, the National Institute…
Transcend Medical Closes $51M Series B Financing
Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, announced the closure of its second tranche, bringing the total of Series B to $51M. Investor Growth Capital (IGC) joined this tranche,…
Histopathologic Complications Seen Post-Intra-Arterial Chemo
Though retinoblastoma can be controlled by intra-arterial chemotherapy (IAC), histopathology demonstrates that ocular complications, including thromboembolic events, can occur, according to a study published online July 11 in the Archives of Ophthalmol…
LensAR Focuses On $2M of $7M Offering for Laser 3D Imaging Tech
Orlando-based LensAR has raised $2 million of a targeted $7 million offering, according to a regulatory filing. The company is developing and commercializing laser and 3D imaging technology for refractive cataract surgery. The company raised $7 million in equity in…
Lupin Sued by Allergan in US Over Eye Drug
The US subsidiary of the Indian drugmaker Lupin has been sued by the US firm Allergan alleging that the former would be infringing its patent coverage by attempting to manufacture and market a generic version of Zymaxid 0.5% (Gatifloxacin opthalmic sol…
Allergan Launches Website to Provide Optometrists Product Information
As part of its “Made for Each Other” campaign, Allergan Inc. has launched a new website, http://www.allerganoptometry.com, which will provide optometrists with single site access to information about Allergan therapeutics including: Informat…
LC-MS Reveals Similarities Between Cataract Incision Procedures
Liquid chromatography-mass spectrometry (LC-MS) analysis of proteins present in aqueous humour obtained from rabbits following cataract surgery incisions has revealed the technique used has little bearing on the response from the eye. A team of scien…
Study Reveals How Omega 3’s Work In Preventing Several Forms Of Blindness
Omega-3 fatty acids – fats commonly found in fish oil – were shown several years ago to prevent retinopathy, a major form of blindness, in a mouse model of the disease. A follow-up study, from the same research team at Children’s Hospital Boston, now…
American Academy of Ophthalmology Launches Eye Health Information Website
The American Academy of Ophthalmology has launched an expanded and authoritative eye health website to help educate consumers about eye diseases and conditions, vision correction and the preservation of healthy vision across a lifetime. The new EyeSm…
Curcumin May Fight Cataract Onset
Oral administration of curcumin may suppress cataract onset and progression in animals, according to a new study (Mol Vis. 2011;17:388-94). Researchers from Alagappa University, Karaikudi, India, investigated how oral administration of curcumin affec…
NICE Consults On Dexamethasone Intravitreal Implant For The Treatment Of Macular Oedema Secondary To Retinal Vein Occlusion
In preliminary recommendations published today (8 February) NICE is asking Allergan for more information on its product dexamethasone (Ozurdex) intravitreal implant, for the treatment of macular oedema secondary to retinal vein occlusion (RVO). The m…
Microplasmin Effective in Two Phase 3 Trials
A single injection of microplasmin (ThromboGenics NV) was effective for the treatment of symptomatic vitreomacular adhesion (VMA), according to the pooled results of two phase 3 trials, TG-MV-006 and TG-MV-007. The findings of the trials, referred to…
Dental Laser Manufacturer Receives Patent For Eye Surgery
@font-face { font-family: “Times”;}@font-face { font-family: “Cambria”;}p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times New Roman”; }h6 { margin: 12pt 0in 3pt; font-size: 11pt; font-family: …
New Method Attacks Bacterial Infections on Contact Lenses
Researchers at National Jewish Health and the University of Texas Southwestern Medical Center have discovered a new method to fight bacterial infections associated with contact lenses. The method may also have applications for bacterial infections as…
Biolase Technology Receives US Patent for Laser Technology in Ophthalmology Field
Med tech company Biolase Technology announced Monday that it has received a new US patent covering the use of its laser technologies for treating farsightedness. The laser-tunneling method covered by the patent mitigates the effects of presbyopia, en…
Alcon Offers BAK-Free Formula Eye Drops
A new formulation of Travatan (40 micrograms/ml eye drops, solution travoprost) has been launched by Alcon Laboratories. It is aimed at addressing the irritation and inflammation some glaucoma patients can experience with preservatives.
Adalimumab May Be Superior to Infliximab in Childhood Uveitis
In children with chronic uveitis, adalimumab appears to be more effective than infliximab in maintaining remission, according to a small cohort study by Italian investigators. Should these results hold up in randomized controlled trials, Dr. Gabriele…